Companies › Xadcera Biopharmaceutical (Suzhou)
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DM001 | – | Phase 1 | Breast Neoplasms | Jan 2027 |
| DM002 | – | Phase 1 | Ovarian Neoplasms | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06475937 | DM001 | Phase 1 | Breast Neoplasms | Oncology | Jan 2027 |
| NCT06751329 | DM002 | Phase 1 | Ovarian Neoplasms | Oncology | Oct 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.